Baltera Robert Jr. 4
4 · PALISADE BIO, INC. · Filed Jul 6, 2026
Research Summary
AI-generated summary of this filing
Palisade Bio (PALI) Director Robert Baltera Jr. Buys 30,000 Shares
What Happened
Robert Baltera Jr., a director of Palisade Bio, purchased a total of 30,000 common shares in two open-market transactions. He bought 20,000 shares on 2026-07-01 for $1.98 per share (total $39,600) and 10,000 shares on 2026-07-02 for $1.98 per share (total $19,800), for an aggregate cost of approximately $59,400. These were purchases (code P), which are generally viewed as insider buying rather than selling.
Key Details
- Transaction dates and amounts:
- 2026-07-01: 20,000 shares acquired at a weighted average $1.98 (≈ $39,600)
- 2026-07-02: 10,000 shares acquired at a weighted average $1.98 (≈ $19,800)
- Aggregate: 30,000 shares acquired for ≈ $59,400.
- Footnote: reported price is a weighted average; actual trade prices ranged from $1.97 to $1.99. The filer will provide a breakdown on request (Footnote F1).
- Filing: Form 4 filed 2026-07-06 covering the 2026-07-01 and 2026-07-02 transactions; this appears to be within normal Section 16 filing timing (filed within the expected business-day window).
- Shares owned after the transactions: not specified in the provided filing details.
Context
These were straightforward open-market purchases (no option exercise, award, or gift involved). Purchases by directors can be of interest to retail investors as a signal that an insider is adding to their position, but they do not prove future performance. The amounts here are modest (~$59.4k total).
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-07-01$1.98/sh+20,000$39,600→ 356,904 total - Purchase
Common Stock
[F1]2026-07-02$1.98/sh+10,000$19,800→ 366,904 total
Footnotes (1)
- [F1]The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.97 to $1.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.